All In Biotech

NDA 220848 · Msd

Lipfendra

Enlicitide Decanoate · Oral

NovelPriority review

CDER novel approval, Jul 15, 2026: To reduce low-density lipoprotein cholesterol

Last checked: Nov 20, 2026Latest source record: Jul 15, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2026

Jul 15, 2026

Approved uses

1

Original approval plus efficacy supplements

Registered trials

26

8 Phase 3, 3 recruiting

FAERS reports

41

6 serious, 0 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jul 15, 2026.

LIPFENDRA ® is indicated as an adjunct to diet and exercise to reduce low-density lipoprotein cholesterol (LDL-C) in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia (HeFH). Cardiovascular outcomes trials have demonstrated that reducing LDL-C lowers the risk for major adverse cardiovascular events (MACE) in adults at increased risk when treated with statins or monoclonal antibody proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitors as an add-on to statin therapy. LIPFENDRA is a proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitor indicated as an adjunct to diet and exercise to reduce low-density lipoprotein cholesterol (LDL-C) in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia (HeFH). Cardiovascular outcomes trials have demonstrated that reducing LDL-C lowers the risk for major adverse cardiovascular events (MACE) in adults at increased risk when treated with statins or monoclonal antibody PCSK9 inhibitors as an add-on to statin therapy. ( 1 )

Mechanism: Enlicitide is a macrocyclic peptide that binds to PCSK9. PCSK9 binds to the low-density lipoprotein receptors (LDLR) on the surface of hepatocytes to promote LDLR degradation within the liver. By inhibiting the binding of PCSK9 to LDLR, enlicitide increases the number of LDLRs available to clear LDL-C, thereby lowering LDL-C levels.

Therapeutic areas: Cardiovascular and metabolic

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jul 15, 2026 Original approval · Type 1 - New Molecular Entity · priority review NovelLetterReviewLabel
1 products under this application
  • LIPFENDRA · ENLICITIDE DECANOATE EQ 20MG BASE · TABLET, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Enlicitide Decanoate" as an intervention, any sponsor and status, largest first.

All 26 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • diarrhoea7
  • dizziness5
  • headache5
  • nausea5
  • fatigue3
  • feeling abnormal3
  • inappropriate schedule of product administration3
  • myalgia3
  • no adverse event3
  • pain in extremity3
  • bladder pain2
  • cerebrovascular accident2

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
202641

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 3 on PubMed

Sponsor: Merck & Co.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.